公开(公告)号：US20140275133A1

公开(公告)日：2014-09-18

申请号：US14350930

申请日：2012-10-08

申请人： Hong Shen ,  Jason M. Cox ,  Hong Dong Chu

发明人： Hong Shen ,  Jason M. Cox ,  Hong Dong Chu

IPC分类号： C07D413/04 ,  C07D413/14 ,  A61K31/4245 ,  A61K31/422 ,  A61K31/506 ,  A61K31/454

CPC分类号： C07D413/04 ,  A61K31/422 ,  A61K31/4245 ,  A61K31/4439 ,  A61K31/454 ,  A61K31/506 ,  C07D263/44 ,  C07D413/14

摘要： The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof that are possible useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the above mentioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).

摘要翻译： 本发明涉及可用于治疗醛固酮介导的疾病的式（I）化合物及其药学上可接受的盐。 本发明还涉及制备式（I）化合物，其可能用于治疗上述疾病和为此目的制备药物的方法，以及包含式（I）化合物的药物组合物。

公开(公告)号：US09193717B2

公开(公告)日：2015-11-24

申请号：US14350888

申请日：2012-10-08

申请人： Hong Shen ,  Christine Yang ,  Jason M. Cox ,  Kun Liu

发明人： Hong Shen ,  Christine Yang ,  Jason M. Cox ,  Kun Liu

IPC分类号： C07D413/04 ,  C07D413/14 ,  C07D403/04 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/5377

CPC分类号： C07D413/04 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/506 ,  A61K31/5377 ,  C07D403/04 ,  C07D413/14

摘要： The present invention is directed to compounds of the Formula (I) as well as pharmaceutically acceptable salts thereof, that are aldosterone receptor antagonists which might be useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula (I), to their possible use for the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula (I).

摘要翻译： 本发明涉及可用于治疗醛固酮介导的疾病的醛固酮受体拮抗剂的式（I）化合物及其药学上可接受的盐。 本发明还涉及制备式（I）化合物，其可能用于治疗上述疾病和为此目的制备药物的方法，以及包含式（I）化合物的药物组合物。

公开(公告)号：US09505730B2

公开(公告)日：2016-11-29

申请号：US14351006

申请日：2012-10-08

申请人： Hong Shen ,  Jason M. Cox ,  Christine Yang ,  Zhicai Wu

发明人： Hong Shen ,  Jason M. Cox ,  Christine Yang ,  Zhicai Wu

IPC分类号： C07D263/44 ,  C07D413/12 ,  C07D413/06 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/4725 ,  C07D401/06 ,  A61K31/421

CPC分类号： C07D263/44 ,  A61K31/421 ,  A61K31/422 ,  A61K31/4439 ,  A61K31/4725 ,  C07D401/06 ,  C07D413/06 ,  C07D413/12

摘要： The present invention is directed to compounds of the Formula I as well as pharmaceutically acceptable salts thereof, that are potentially useful for treating aldosterone-mediated diseases. The invention furthermore relates to processes for preparing compounds of the Formula I, to their possible use in the treatment of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical compositions which comprise compounds of the Formula I.

公开(公告)号：US09284301B2

公开(公告)日：2016-03-15

申请号：US13636760

申请日：2011-03-22

申请人： Darby Schmidt ,  Subharekha Raghavan ,  John Stelmach ,  Jian Guo ,  Jonathan Groeper ,  Linda Brockunier ,  Keith Rosauer ,  Hong Shen ,  Rui Liang ,  Fa-Xiang Ding

发明人： Darby Schmidt ,  Subharekha Raghavan ,  John Stelmach ,  Jian Guo ,  Jonathan Groeper ,  Linda Brockunier ,  Keith Rosauer ,  Hong Shen ,  Rui Liang ,  Fa-Xiang Ding

IPC分类号： C07D403/14 ,  C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

CPC分类号： C07D403/14 ,  C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

摘要： The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

摘要翻译： 本发明涉及具有式（I）结构的化合物及其药学上可接受的盐，它们是可溶性鸟苷酸环化酶活化剂。 这些化合物能够调节人体的环鸟苷酸（“cGMP”）的产生，并且通常适用于治疗和预防与受干扰的cGMP平衡有关的疾病。 该化合物可用于治疗或预防心血管疾病，内皮功能障碍，舒张功能障碍，动脉粥样硬化，高血压，肺动脉高压，心绞痛，血栓形成，再狭窄，心肌梗死，中风，心功能不全，肺性高血压，勃起功能障碍，支气管哮喘，慢性 肾功能不全，糖尿病或肝硬化。

公开(公告)号：US20130193573A1

公开(公告)日：2013-08-01

申请号：US13360489

申请日：2012-01-27

申请人： Hong Shen

发明人： Hong Shen

IPC分类号： H01L23/48 ,  H01L21/28 ,  H01L21/66

CPC分类号： H01L29/452 ,  H01L21/76898 ,  H01L21/8252 ,  H01L24/45 ,  H01L24/48 ,  H01L24/83 ,  H01L24/97 ,  H01L27/02 ,  H01L29/20 ,  H01L33/12 ,  H01L2224/0401 ,  H01L2224/04026 ,  H01L2224/05647 ,  H01L2224/05655 ,  H01L2224/05664 ,  H01L2224/13101 ,  H01L2224/29294 ,  H01L2224/293 ,  H01L2224/32225 ,  H01L2224/32245 ,  H01L2224/45124 ,  H01L2224/45144 ,  H01L2224/45147 ,  H01L2224/48091 ,  H01L2224/48227 ,  H01L2224/48247 ,  H01L2224/48647 ,  H01L2224/48655 ,  H01L2224/48664 ,  H01L2224/48747 ,  H01L2224/48755 ,  H01L2224/48764 ,  H01L2224/48847 ,  H01L2224/48855 ,  H01L2224/48864 ,  H01L2224/73265 ,  H01L2224/81815 ,  H01L2224/83192 ,  H01L2224/83815 ,  H01L2224/85205 ,  H01L2224/85207 ,  H01L2224/97 ,  H01L2924/00011 ,  H01L2924/10329 ,  H01L2924/12042 ,  H01L2924/1305 ,  H01L2924/15311 ,  H01L2924/15313 ,  H01L2924/181 ,  H01L2924/00014 ,  H01L2924/014 ,  H01L2224/83 ,  H01L2924/00 ,  H01L2224/83205 ,  H01L2924/00012

摘要： Systems, apparatuses, and methods related to the design, fabrication, and manufacture of gallium arsenide (GaAs) integrated circuits are disclosed. Copper can be used as the contact material for a GaAs integrated circuit. Metallization of the wafer and through-wafer vias can be achieved through copper plating processes disclosed herein. To avoid warpage, the tensile stress of a conductive layer deposited onto a GaAs substrate can be offset by depositing a compensating layer having negative stress over the GaAs substrate. GaAs integrated circuits can be singulated, packaged, and incorporated into various electronic devices.

公开(公告)号：US20130012511A1

公开(公告)日：2013-01-10

申请号：US13636760

申请日：2011-03-22

申请人： Darby Schmidt ,  Subharekha Raghavan ,  John Stelmach ,  Jian Guo ,  Jonathan Groeper ,  Linda Brockunier ,  Keith Rosauer ,  Hong Shen ,  Rui Liang ,  Fa-Xiang Ding

发明人： Darby Schmidt ,  Subharekha Raghavan ,  John Stelmach ,  Jian Guo ,  Jonathan Groeper ,  Linda Brockunier ,  Keith Rosauer ,  Hong Shen ,  Rui Liang ,  Fa-Xiang Ding

IPC分类号： C07D403/14 ,  A61K31/506 ,  C07D471/04 ,  C07D401/14 ,  C07D413/14 ,  A61K31/5377 ,  C07D417/14 ,  C07D403/04 ,  A61P9/00 ,  A61P9/10 ,  A61P9/12 ,  A61P9/04 ,  A61P7/02 ,  A61P11/00 ,  A61P15/00 ,  A61P11/06 ,  A61P13/12 ,  A61P3/10 ,  A61P1/16 ,  A61P9/08 ,  A61P7/10 ,  A61P3/00 ,  A61P3/06 ,  C07D487/04

CPC分类号： C07D403/14 ,  C07D401/14 ,  C07D403/04 ,  C07D413/14 ,  C07D417/14 ,  C07D471/04 ,  C07D487/04

摘要： The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

摘要翻译： 本发明涉及具有式（I）结构的化合物及其药学上可接受的盐，它们是可溶性鸟苷酸环化酶活化剂。 这些化合物能够调节身体产生的环鸟苷酸（cGMP），通常适用于治疗和预防与受干扰的cGMP平衡有关的疾病。 该化合物可用于治疗或预防心血管疾病，内皮功能障碍，舒张功能障碍，动脉粥样硬化，高血压，肺动脉高压，心绞痛，血栓形成，再狭窄，心肌梗死，中风，心功能不全，肺性高血压，勃起功能障碍，支气管哮喘，慢性 肾功能不全，糖尿病或肝硬化。

公开(公告)号：US20120226051A1

公开(公告)日：2012-09-06

申请号：US13509985

申请日：2010-11-12

申请人： Shaohua Gou ,  Hong Shen ,  Yindi Zhang ,  Jianping Shen ,  Yanqin Zhu ,  Luzhong Feng ,  Jianwei Wu ,  Dekang Chen

发明人： Shaohua Gou ,  Hong Shen ,  Yindi Zhang ,  Jianping Shen ,  Yanqin Zhu ,  Luzhong Feng ,  Jianwei Wu ,  Dekang Chen

IPC分类号： C07D231/56 ,  C07D233/64

CPC分类号： C07D231/56

摘要： Organic dicarboxylic acid compounds, salts and preparation methods thereof. The said compounds have activity of resisting oxidation damage to crystalline lens of eyes. The structures of the above organic dicarboxylic acid compounds are shown as formula (1).

摘要翻译： 有机二羧酸化合物，其盐及其制备方法。 所述化合物具有抵抗眼睛晶状体的氧化损伤的活性。 上述有机二羧酸化合物的结构如式（1）所示。

公开(公告)号：US20120153476A1

公开(公告)日：2012-06-21

申请号：US12971465

申请日：2010-12-17

申请人： Hong Shen

发明人： Hong Shen

IPC分类号： H01L23/48 ,  H01L21/768

CPC分类号： H01L21/76898 ,  H01L21/3081 ,  H01L21/6835 ,  H01L2221/68327 ,  H01L2221/6834 ,  H01L2221/68381

摘要： Etched wafers and methods of forming the same are disclosed. In one embodiment, a method of etching a wafer is provided. The method includes forming a metal hard mask on the wafer using electroless plating, patterning the metal hard mask, and etching a plurality of features on the wafer using an etcher. The plurality of featured are defined by the metal hard mask.

摘要翻译： 公开了蚀刻的晶片及其形成方法。 在一个实施例中，提供了蚀刻晶片的方法。 该方法包括使用化学镀在晶片上形成金属硬掩模，图案化金属硬掩模，以及使用蚀刻器蚀刻晶片上的多个特征。 多个特征由金属硬掩模定义。

公开(公告)号：US08107699B2

公开(公告)日：2012-01-31

申请号：US12170639

申请日：2008-07-10

申请人： Lin Hong ,  Christopher V. Alvino ,  Hong Shen

发明人： Lin Hong ,  Christopher V. Alvino ,  Hong Shen

IPC分类号： G06K9/00

CPC分类号： G06T7/0012 ,  G06T2207/30061 ,  G06T2207/30064

摘要： Feature processing is provided for lung nodules in computer-assisted diagnosis. A feature that may better distinguish nodules from background is extracted using a Hough transform. Rather than relying on a specific boundary shape, the Hough transform accumulates evidence associated with a region, such as a ring region. The accumulated evidence provides a feature score without requiring a nodule to fit a specific shape. In another approach, a background level is determined from extracted features. Rather than attempting to normalize an image prior to extraction, the features are normalized. The feature normalization and generalized Hough transform extraction may be used together or alone.

摘要翻译： 在计算机辅助诊断中为肺结节提供特征处理。 使用霍夫变换提取可以更好地区分结节与背景的特征。 霍夫变换不是依赖于特定的边界形状，而是累积与区域相关联的证据，例如环形区域。 积累的证据提供了一个特征分数，而不需要结节来适应特定的形状。 在另一种方法中，从提取的特征确定背景级别。 在尝试在提取之前对图像进行归一化，而不是将特征归一化。 特征归一化和广义霍夫变换提取可以一起使用或单独使用。

公开(公告)号：US08103077B2

公开(公告)日：2012-01-24

申请号：US11951372

申请日：2007-12-06

申请人： Lin Hong ,  Ying Li ,  Hong Shen

发明人： Lin Hong ,  Ying Li ,  Hong Shen

IPC分类号： G06K9/00

CPC分类号： G06T7/12

摘要： A method and system for locating an opaque region, such as a heart region in a chest X-ray radiograph is disclosed. In order to segment a heart region in a chest X-ray radiograph, a heart region boundary is generated based on lung boundaries in the chest X-ray radiograph and an average heart region model. A location of the lower boundary of the heart region in the chest X-ray radiograph is then determined. Left and right portions of the heart region boundary are independently registered to corresponding portions of the lung boundaries, and upper and lower portions of the heart region boundary are adjusted based on the left and right portions in order to form a smooth contour.

摘要翻译： 公开了一种用于定位不透明区域的方法和系统，例如胸部X射线照片中的心脏区域。 为了在胸部X射线照片中分割心脏区域，基于胸部X射线照片和平均心脏区域模型中的肺边界产生心脏区域边界。 然后确定胸部X线片中的心脏区域的下边界的位置。 心脏区域边界的左右部分独立地登记到肺边界的对应部分，并且基于左右部分来调整心脏区域边界的上部和下部以形成平滑轮廓。